Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy

Figures & data

Table 1 Comparison of Outcomes Pre-Omalizumab and One Year Post-Commencement of Omalizumab, and Established on Omalizumab Pre-Switching to Anti-IL-5 Therapy and One Year Post-Commencement of Anti-IL-5 Therapy

Variable	Pre-Omalizumab	1 Year Post-Omalizumab	p-Value	Pre-Anti-IL-5	1 Year Post-Anti-IL-5	p-Value
Asthma Control Questionnaire	3.4 (2.4–5.0)	3.0 (1.6–3.8)	0.465	3.0 (1.7–3.3)	1.9 (0–4.0)	0.352
Hospital exacerbations/year	1.5 (0–4)	0 (0–2)	0.056	0 (0–3)	0 (0–2)	0.564
Community exacerbations/year	10 (4–12)	5 (0–9)	0.043	6 (4–24)	0 (0–6)	0.005
Serum eosinophil count (×10^9/L)	0.50 (0.19–1.5)	0.60 (0.12–1.0)	1.00	0.70 (0.09–1.10)	0 (0–0.66)	0.007
Maintenance OCS (mg)	9.0 (0–20.0)	10.0 (0–15.0)	0.892	7.5 (0–15.0)	2.5 (0–15.0)	0.276
FEV1 (% predicted)	56 (30–79)	57 (40–82)	1.00	62 (36–103)	76 (31–116)	0.046

Note: Data are expressed as median (range).